Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26448946 | 1.00 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL26959605 | 1.00 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL29296256 | 0.88 | PIK3CD (0.37) | PIK3CDLMNACYP2C9 | |
| SCHEMBL888602 | 0.78 | PIK3CD (0.50) | PIK3CDLMNACYP2C9 | |
| SCHEMBL19131027 | 0.78 | PIK3CD (0.50) | PIK3CDLMNACYP2C9 | |
| SCHEMBL29302247 | 0.78 | PIK3CD (0.50) | PIK3CDLMNACYP2C9 | |
| SCHEMBL24729566 | 0.78 | PIK3CD (0.50) | PIK3CDLMNACYP2C9 | |
| SCHEMBL15429769 | 0.78 | PIK3CD (0.50) | PIK3CDLMNACYP2C9 | |
| SCHEMBL9892343 | 0.78 | PIK3CD (0.50) | PIK3CDLMNACYP2C9 | |
| SCHEMBL2706023 | 0.77 | L3MBTL1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021158899-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | EEF1A1, EEF1B2, EEF1G | PIK3CD 2447/4885LMNA 2822/4885CYP2C9 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.